Shopping Cart 0
Cart Subtotal
USD 0

Alopecia - Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Alopecia-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alopecia-Pipeline Review, H2 2018, provides an overview of the Alopecia (Dermatology) pipeline landscape.

Alopecia is the partial or complete loss of hair especially on the scalp either in patches, on the entire head or over the entire body. Thinning hair is the most obvious symptom. The predisposing factors include allergies, irritants, toxins, burns, injuries, and infections.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alopecia-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Alopecia (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alopecia (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Alopecia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 16, 8, 1, 17 and 10 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Alopecia (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Alopecia (Dermatology).

- The pipeline guide reviews pipeline therapeutics for Alopecia (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Alopecia (Dermatology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Alopecia (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Alopecia (Dermatology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Alopecia (Dermatology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Alopecia (Dermatology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

Introduction 5

Alopecia-Overview 6

Alopecia-Therapeutics Development 7

Alopecia-Therapeutics Assessment 17

Alopecia-Companies Involved in Therapeutics Development 27

Alopecia-Drug Profiles 41

Alopecia-Dormant Projects 144

Alopecia-Discontinued Products 147

Alopecia-Product Development Milestones 148

Appendix 156


List Of Figure

List of Figures

Number of Products under Development for Alopecia, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development for Alopecia, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Target, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Alopecia-Pipeline by Aclaris Therapeutics Inc, H2 2018

Alopecia-Pipeline by Allergan Plc, H2 2018

Alopecia-Pipeline by Almirall SA, H2 2018

Alopecia-Pipeline by AndroScience Corp, H2 2018

Alopecia-Pipeline by Berg LLC, H2 2018

Alopecia-Pipeline by BiologicsMD Inc, H2 2018

Alopecia-Pipeline by BirchBioMed Inc, H2 2018

Alopecia-Pipeline by Brickell Biotech Inc, H2 2018

Alopecia-Pipeline by Bristol-Myers Squibb Co, H2 2018

Alopecia-Pipeline by Cassiopea SpA, H2 2018

Alopecia-Pipeline by Concert Pharmaceuticals Inc, H2 2018

Alopecia-Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2018

Alopecia-Pipeline by Dong-A Socio Holdings Co Ltd, H2 2018

Alopecia-Pipeline by Eli Lilly and Co, H2 2018

Alopecia-Pipeline by Energenesis Biomedical Co Ltd, H2 2018

Alopecia-Pipeline by Follica Inc, H2 2018

Alopecia-Pipeline by Histogen Inc, H2 2018

Alopecia-Pipeline by Japan Tobacco Inc, H2 2018

Alopecia-Pipeline by JW Pharmaceutical Corp, H2 2018

Alopecia-Pipeline by Kuhnil Pharmaceutical Co Ltd, H2 2018

Alopecia-Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2018

Alopecia-Pipeline by Medivir AB, H2 2018

Alopecia-Pipeline by NovaLead Pharma Pvt Ltd, H2 2018

Alopecia-Pipeline by OliX Pharmaceuticals Inc, H2 2018

Alopecia-Pipeline by Pfizer Inc, H2 2018

Alopecia-Pipeline by Portola Pharmaceuticals Inc, H2 2018

Alopecia-Pipeline by Quark Pharmaceuticals Inc, H2 2018

Alopecia-Pipeline by RXi Pharmaceuticals Corp, H2 2018

Alopecia-Pipeline by Samumed LLC, H2 2018

Alopecia-Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H2 2018

Alopecia-Pipeline by Tigo GmbH, H2 2018

Alopecia-Dormant Projects, H2 2018

Alopecia-Dormant Projects, H2 2018 (Contd..1), H2 2018

Alopecia-Dormant Projects, H2 2018 (Contd..2), H2 2018

Alopecia-Discontinued Products, H2 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Alopecia Therapeutic Products under Development, Key Players in Alopecia Therapeutics, Alopecia Pipeline Overview, Alopecia Pipeline, Alopecia Pipeline Assessment


Companies

Aclaris Therapeutics Inc

Allergan Plc

Almirall SA

AndroScience Corp

Berg LLC

BiologicsMD Inc

BirchBioMed Inc

Brickell Biotech Inc

Bristol-Myers Squibb Co

Cassiopea SpA

Concert Pharmaceuticals Inc

Daewoong Pharmaceutical Co Ltd

Dong-A Socio Holdings Co Ltd

Eli Lilly and Co

Energenesis Biomedical Co Ltd

Follica Inc

Histogen Inc

Japan Tobacco Inc

JW Pharmaceutical Corp

Kuhnil Pharmaceutical Co Ltd

Lee's Pharmaceutical Holdings Ltd

Medivir AB

NovaLead Pharma Pvt Ltd

OliX Pharmaceuticals Inc

Pfizer Inc

Portola Pharmaceuticals Inc

Quark Pharmaceuticals Inc

RXi Pharmaceuticals Corp

Samumed LLC

Taisho Pharmaceutical Holdings Co Ltd

Tigo GmbH

Alopecia-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alopecia-Pipeline Review, H2 2018, provides an overview of the Alopecia (Dermatology) pipeline landscape.

Alopecia is the partial or complete loss of hair especially on the scalp either in patches, on the entire head or over the entire body. Thinning hair is the most obvious symptom. The predisposing factors include allergies, irritants, toxins, burns, injuries, and infections.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alopecia-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Alopecia (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alopecia (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Alopecia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 16, 8, 1, 17 and 10 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Alopecia (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Alopecia (Dermatology).

- The pipeline guide reviews pipeline therapeutics for Alopecia (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Alopecia (Dermatology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Alopecia (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Alopecia (Dermatology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Alopecia (Dermatology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Alopecia (Dermatology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

Table of Contents 2

Introduction 5

Alopecia-Overview 6

Alopecia-Therapeutics Development 7

Alopecia-Therapeutics Assessment 17

Alopecia-Companies Involved in Therapeutics Development 27

Alopecia-Drug Profiles 41

Alopecia-Dormant Projects 144

Alopecia-Discontinued Products 147

Alopecia-Product Development Milestones 148

Appendix 156


List Of Figure

List of Figures

Number of Products under Development for Alopecia, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development for Alopecia, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Target, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Alopecia-Pipeline by Aclaris Therapeutics Inc, H2 2018

Alopecia-Pipeline by Allergan Plc, H2 2018

Alopecia-Pipeline by Almirall SA, H2 2018

Alopecia-Pipeline by AndroScience Corp, H2 2018

Alopecia-Pipeline by Berg LLC, H2 2018

Alopecia-Pipeline by BiologicsMD Inc, H2 2018

Alopecia-Pipeline by BirchBioMed Inc, H2 2018

Alopecia-Pipeline by Brickell Biotech Inc, H2 2018

Alopecia-Pipeline by Bristol-Myers Squibb Co, H2 2018

Alopecia-Pipeline by Cassiopea SpA, H2 2018

Alopecia-Pipeline by Concert Pharmaceuticals Inc, H2 2018

Alopecia-Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2018

Alopecia-Pipeline by Dong-A Socio Holdings Co Ltd, H2 2018

Alopecia-Pipeline by Eli Lilly and Co, H2 2018

Alopecia-Pipeline by Energenesis Biomedical Co Ltd, H2 2018

Alopecia-Pipeline by Follica Inc, H2 2018

Alopecia-Pipeline by Histogen Inc, H2 2018

Alopecia-Pipeline by Japan Tobacco Inc, H2 2018

Alopecia-Pipeline by JW Pharmaceutical Corp, H2 2018

Alopecia-Pipeline by Kuhnil Pharmaceutical Co Ltd, H2 2018

Alopecia-Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2018

Alopecia-Pipeline by Medivir AB, H2 2018

Alopecia-Pipeline by NovaLead Pharma Pvt Ltd, H2 2018

Alopecia-Pipeline by OliX Pharmaceuticals Inc, H2 2018

Alopecia-Pipeline by Pfizer Inc, H2 2018

Alopecia-Pipeline by Portola Pharmaceuticals Inc, H2 2018

Alopecia-Pipeline by Quark Pharmaceuticals Inc, H2 2018

Alopecia-Pipeline by RXi Pharmaceuticals Corp, H2 2018

Alopecia-Pipeline by Samumed LLC, H2 2018

Alopecia-Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H2 2018

Alopecia-Pipeline by Tigo GmbH, H2 2018

Alopecia-Dormant Projects, H2 2018

Alopecia-Dormant Projects, H2 2018 (Contd..1), H2 2018

Alopecia-Dormant Projects, H2 2018 (Contd..2), H2 2018

Alopecia-Discontinued Products, H2 2018

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Alopecia Therapeutic Products under Development, Key Players in Alopecia Therapeutics, Alopecia Pipeline Overview, Alopecia Pipeline, Alopecia Pipeline Assessment


Companies

Aclaris Therapeutics Inc

Allergan Plc

Almirall SA

AndroScience Corp

Berg LLC

BiologicsMD Inc

BirchBioMed Inc

Brickell Biotech Inc

Bristol-Myers Squibb Co

Cassiopea SpA

Concert Pharmaceuticals Inc

Daewoong Pharmaceutical Co Ltd

Dong-A Socio Holdings Co Ltd

Eli Lilly and Co

Energenesis Biomedical Co Ltd

Follica Inc

Histogen Inc

Japan Tobacco Inc

JW Pharmaceutical Corp

Kuhnil Pharmaceutical Co Ltd

Lee's Pharmaceutical Holdings Ltd

Medivir AB

NovaLead Pharma Pvt Ltd

OliX Pharmaceuticals Inc

Pfizer Inc

Portola Pharmaceuticals Inc

Quark Pharmaceuticals Inc

RXi Pharmaceuticals Corp

Samumed LLC

Taisho Pharmaceutical Holdings Co Ltd

Tigo GmbH